The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study
Sequential treatment with ADCs showed clinical benefit especially for HER2-positive patients treated with ADC2 which have different types of payloads from ADC1. In HER2-low patients, the benefit of ADC sequential therapy seemed to be limited.
Authors
- Lixi Li (ORCID: https://orcid.org/0000-0001-5790-5052)
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Hongnan Mo (ORCID: https://orcid.org/0000-0002-2887-7985)
- Xuenan Peng
- Bo Lan (ORCID: https://orcid.org/0000-0002-2962-439X)
- Jiayu Wang (ORCID: https://orcid.org/0000-0003-0470-0322)
- Qiao Li (ORCID: https://orcid.org/0000-0002-4547-1266)
- Jintao Zhang (ORCID: https://orcid.org/0000-0002-1029-3404)
- Shanshan Chen (ORCID: https://orcid.org/0000-0001-9723-2403)
- Yang Luo (ORCID: https://orcid.org/0000-0002-5501-9935)
- Binghe Xu (ORCID: https://orcid.org/0000-0002-0234-2747)
- Pin Zhang (ORCID: https://orcid.org/0000-0001-8903-3666)
- Jiani Wang (ORCID: https://orcid.org/0000-0002-0869-3468)
- Xiaoying Sun (ORCID: https://orcid.org/0000-0001-7503-3921)
- Ying Fan (ORCID: https://orcid.org/0000-0003-3419-9399)
- Ruigang Cai
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Publication Details
- Journal
- The Breast
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.breast.2025.104470
- Citations
- 6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- National Natural Science Foundation of China
- Chinese Academy of Meteorological Sciences